R. King Milling serves as leader of Orrick’s global Corporate Business Unit, which includes its Corporate, Capital Markets, Compensation & Benefits, Technology Companies, Emerging Markets, M&A and Private Equity and Tax groups.

King is a partner in the New York office and a member of the Global Mergers & Acquisitions and Private Equity Group. His practice focuses on domestic and cross-border M&A, joint venture, private equity and venture capital transactions, including negotiated mergers, auction bid processes, distressed asset sales, leveraged buyouts and the acquisition and divestiture of divisions and subsidiaries.

King is experienced in all aspects of Delaware and New York corporate, partnership and limited liability company law. He regularly counsels boards of directors on corporate governance, compliance, fiduciary duty and executive compensation matters.

King represents U.S. and non-U.S. clients in a wide range of industries, including life sciences, technology, energy, consumer products, industrials and manufacturing and financial services.

  • King’s recent transactions include representing:

    • Par Pharmaceutical Companies, Inc., at the time a NYSE-listed developer, manufacturer and marketer of generic drugs, in its $1.9 billion all cash acquisition by the private equity firm TPG.
    • Par Pharmaceutical in its $410 million acquisition of Anchen Pharmaceuticals.
    • Paddock Labs, a privately-held manufacturer and marketer of generic pharmaceutical products, in its $540 million sale to Perrigo Co., a leading global healthcare supplier.
    • CoorsTek, Inc. a leading global manufacturer of technical ceramic and specialty material components, in its $245 million acquisition of the Advanced Ceramics business of Saint-Gobain, a French multinational corporation, as well as in a number of other transactions.
    • Ensyn Corporation, a leading producer of renewable liquid fuels and renewable chemical products, in its joint venture with UOP, a Honeywell company, as well as in various other transactions.
    • ORIX USA Corporation, a leading corporate lender and finance company, in various transactions.
    • Instinet, a global leader in electronic trading and agency-only brokerage services, in various acquisitions.
    • Macquarie Group, global provider of financial, advisory, investment and funds management services, in various acquisitions and other infrastructure transactions.
    • eCORP, a leader in the development and operation of natural gas storage facilities, in various joint venture and infrastructure transactions.
    • Sigma-Tau Pharmaceuticals, Inc., a marketer of pharmaceutical products treating rare diseases, in its $327 million acquisition of the specialty products division of Enzon Pharmaceuticals, Inc., as well as in a number of other transactions.
    • OPG Groep N.V., a pharmaceutical distribution firm, in its $132 million acquisition of Byram Healthcare, a provider of medical supplies for home healthcare and related services.

News